
    
      The study is a prospective, multi-center, single arm study that will enroll a maximum of 90
      subjects, plus up to 50 roll-in subjects. A maximum of 10 sites in Europe will be involved in
      this study. The primary performance endpoint is successful revascularization defined as TICI
      2b-3 flow in the target vessel post-treatment of up to three passes with the DAISe System.
      The primary safety endpoint is symptomatic intracranial haemorrhage at 24 hours
      post-procedure as detected by CT/MRI with an NIHSS change of >/=4. Subject will be followed
      through hospital discharge with a visit at Day 1 post procedure, Day 7 or prior to
      discharge/transfer, 30 days and 3 months.
    
  